Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.23, $0.05 worse than the analyst estimate of $2.28. Revenue for the quarter came in at $6.505 billion versus the consensus estimate of $6.62 billion.

Reiterates Full Year 2017 Guidance

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.